Medtronic Aktie News

Medtronic is regaining momentum, driven by double-digit growth in key cardiac franchises and a raised full-year revenue outlook. MDT's pulsed-field ablation business surged, with U.S. PFA sales more than tripling, fueling overall cardiovascular strength. Management is shifting to a growth mindset, scaling manufacturing and R&D to capture underpenetrated markets, while maintaining a strong balan...

Enterprise Products Partners will produce significantly more free cash flow in 2026. Medtronic is only two years away from achieving a rare dividend milestone.

GALWAY, Ireland , Dec. 4, 2025 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE: MDT) on Thursday, December 4, 2025, approved the company's cash dividend for the third quarter of fiscal year 2026 of $0.71 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in May 2025.

Medtronic recently delivered strong quarterly results thanks to a fast-growing franchise. This tailwind, along with others, could help maintain the stock's momentum into 2026.

Hugo RAS system brings choice to the U.S., coupled with the full suite of Medtronic surgical offerings, ultimately creating a connected and integrated operating room today and into the future. GALWAY, Ireland , Dec. 3, 2025 /PRNewswire/ -- Medtronic (NYSE: MDT), a global leader in surgical innovation, today announced the U.S. Food and Drug Administration (FDA) has cleared the Hugo™ robotic-assi...

GALWAY, Ireland , Dec. 2, 2025  /PRNewswire/ -- Medtronic (NYSE: MDT), a global leader in healthcare technology, today announced the broad U.S. commercial launch of the MiniMed™ 780G system integrated with the Instinct sensor, made by Abbott and designed exclusively for MiniMed™ systems. Following U.S. FDA clearance of the system earlier this year to enable integration with the Instinct sensor,...

Intuitive Surgical shows why now is a good time to consider buying surgical-robot competitor Medtronic. Eli Lilly helps explain why down-and-out drugmaker Pfizer could be worth a close look for long-term investors.

The ProShares S&P 500 Dividend Aristocrats ETF (NOBL) has underperformed the SPDR S&P 500 ETF (SPY) year-to-date, but November shows a reversal. Several Dividend Aristocrats, including CAH, CAT, CHRW, and ALB, have posted double-digit gains in 2025, while others lag behind. Dividend growth among Aristocrats averages 5.46% for 2025, with most constituents announcing increases, though growth is s...